Maralixibat for the treatment of intrahepatic cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy (ICP) is a common liver problem affecting thousands of UK pregnancies each year. It causes uncomfortable itching and raises levels of bile acids in the blood, which can sometimes lead to premature birth. Existing treatments do not always give enough relief, so doctors are looking for better options. The METAPHOR clinical trial is testing a medicine called maralixibat. Maralixibat is already used to treat liver problems in children. It works directly in the gut to help clear extra bile acids out of the body, rather than travelling through the bloodstream. Researchers at Imperial College London are testing maralixibat in 28 pregnant women to check its safety, see if it soothes severe itching, and find out whether it lowers bile acid levels until delivery.
Em resumo
Sobre o que é este estudo?
Intrahepatic cholestasis of pregnancy (ICP) is a liver condition that affects around 5,500 pregnant women in the UK every year. The liver makes substances called bile acids to help digest food. During pregnancy, hormones can slow down the normal flow of these bile acids, causing them to build up in the mother's blood. This can trigger intense itching, which often disturbs sleep, and can also increase the risk of the baby being born early.
While doctors have ways to monitor and treat ICP, current medicines do not work well for everyone. The METAPHOR study is looking at a new treatment called maralixibat. This medicine is already used safely in children with other liver conditions. Researchers hope it can help pregnant women with ICP by binding to bile acids in the digestive system and removing them through the bowel.
Because maralixibat stays mostly in the gut and is barely absorbed into the blood, scientists believe it is unlikely to spread widely through the mother's body or harm the baby. However, this is the first time it is being tested in pregnancy. This study will carefully check how well it works, how safe it is, and whether it can improve comfort and peace of mind during pregnancy.
Pontos principais
- The METAPHOR trial is testing a medicine called maralixibat for intrahepatic cholestasis of pregnancy (ICP).
- ICP causes severe itching and raises bile acid levels in the blood, which can pose risks to the baby.
- Maralixibat works in the gut to help remove extra bile acids before they build up in the body.
- The study is open to pregnant women aged 18 to 50 between 20 and 34 weeks of pregnancy.
- All participants receive the study medicine, and health checks will continue until delivery.
Quem pode ser elegível?
You may be able to join this study if you are a pregnant woman aged between 18 and 50 years old, carrying one baby or twins, and are between 20 and 34 weeks pregnant. You must be receiving your pregnancy care at an NHS hospital running the trial.
To take part, you need a confirmed diagnosis of ICP. This means you have itching that started during your pregnancy with no other obvious cause, and blood tests showing high bile acid levels (19 micromoles per litre or higher).
You will not be able to join if you have certain other ongoing liver conditions. You will also be asked to avoid specific medications during the study, such as certain immune-system medicines or cholesterol drugs called statins. If you take medicines like steroids or certain antidepressants, you must have been on a steady dose for at least 12 weeks.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- I am between 18 and 50 years old.
- I am currently between 20 and 34 weeks pregnant (with one baby or twins).
- I have been diagnosed with ICP and have unexplained itching in pregnancy.
- A recent blood test showed my bile acid level was 19 µmol/L or higher.
- I am receiving antenatal care at a participating NHS hospital.
- I do not have other chronic liver conditions.
O que envolve a participação?
If you take part, you will be given maralixibat to take every day until your baby arrives. You will start on a lower dose, which the research team can adjust if needed. Everyone in this trial receives the real medicine; there is no dummy pill (placebo). Throughout your pregnancy, you will have regular hospital visits alongside your normal antenatal appointments. The team will take blood samples to monitor your bile acid levels and your liver health. You will also be asked to fill in a weekly questionnaire about your itching to track how you are feeling. The study team will stay in touch and monitor you and your baby until birth.
Riscos e benefícios potenciais
Localizações (1)
- -Não verificado-, England
Perguntas frequentes
Will taking this medicine pass into my bloodstream and reach my baby?
Maralixibat works locally inside your gut and is barely absorbed into your blood. Researchers expect that very little, if any, will travel to your baby, though safety is being carefully checked in this trial.
Is there a placebo (dummy medicine) in this trial?
No. All 28 women who join this study will receive the active study medicine, maralixibat.
How long will I take the study medicine?
You will take the medicine every day from when you join the study until you give birth to your baby.
What happens if I experience side effects like diarrhoea?
The study team will start you on a low dose to reduce this risk. If you do get tummy upsets, let the study doctors know so they can review your dose or help manage your symptoms.
Posso sair do estudo se mudar de ideia?
Yes. You are free to stop taking part at any time. Your decision will not change the quality of your regular NHS pregnancy care in any way.
Como saber mais
Amalia Ndoutoumou
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.